Phenotype Assessment of Blood and Airway Eosinophils in Patients With COPD and Asthma
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- expression of surface markers
研究概览
简要总结
Around 1/3 of patients with COPD have elevated eosinophil levels. However, the role of eosinophils in COPD has not been yet understood and is probably different in COPD and in asthma. The aim of this study was to assess the expression of selected surface markers on eosinophils and to assess the gene expression in eosinophils in COPD and asthma patients. We are planning to enrol 12 COPD, 12 asthma and 12 control subjects. Patients will undergo routine clinical assessment, spirometry, blood sampling and sputum induction. Eosinophils will be isolated from blood and sputum. Surface markers on eosinophils will be assessed in flow cytometry, gene expression will be assessed by RNAseq.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Diagnosis of COPD according to GOLD 2019 or asthma according to GINA 2021
- •Peripheral blood eosinophil count ≥ 100 / μL
- •Age ≥40 years (COPD), ≥18 years (asthma)
- •History of cigarette smoking: ≥10 pack-years (for COPD)
- •Stable disease period (at least 3 months without exacerbation)
- •Exclusion of parasitic diseases
- •Informed consent to participate in the study
排除标准
- •COPD and asthma overlap
- •Use of systemic corticosteroids in the 3 months prior to the study
- •Respiratory infection or exacerbation in the 3 months prior to the study
- •Acute and chronic respiratory failure
- •Concomitant diagnoses: systemic connective tissue diseases, malignant neoplasms, severe and / or uncontrolled cardiovascular diseases
- •Use of immunosuppressive or immunomodulating drugs in the 3 months preceding the study
- •Contraindications to sputum induction
- •No consent to participate in the study
结局指标
主要结局
expression of surface markers
时间窗: performed up to 3 months after blood and sputum collection
expression of CD125, CD62L, CD66b, CD193, CD11b, CD14
次要结局
未报告次要终点